and additional detection of the bound dSHBG with 100 L of 0.5 mg/L peroxidase-linked RCA 120 in BSA/PB. Because this lectin can bind to immobilized immunoglobulins through their carbohydrate moiety, we ran a blank test in which no serum was added; the absorbances of these blanks, always Ͻ0.15, were acceptable. Concentrations of the dSHBG standard solutions ranged from 0 to 500 g/L (Fig. 1B) . Serum samples were usually diluted 1:286 and 1:546 in BSA/PB; however, for some patients, higher dilutions had to be tested. All determinations were done in duplicate, and data were analyzed as previously described for total SHBG.
The within-run CV for duplicates was ϳ7% (n ϭ 173), and mean analytical recovery (overload ϭ 30 g/L) was 105% (SD ϭ 17%, n ϭ 40). Because the in vivo desialylation process may affect the glycan chains differently, serum probably contains several SHBG isoforms with various sialic acid or terminal galactosyl residues contents and thus with different reactivities toward RCA 120 . Because of this heterogeneity in the serum isoform profile, the use of in vitro neuraminidase-treated SHBG as a standard is questionable. Serum dSHBG concentrations were thus expressed as arbitrary units, one unit being defined as the absorbance obtained with a 1 g/L dSHBG calibrator. In healthy donors, values range from 9 to 12 U/L, whereas in some patients with hepatic diseases, concentrations may rise to 100 U/L. SHBG and dSHBG can be determined in parallel easily using the described procedures because most of the steps are similar: coating with anti-SHBG antibody, BSA saturation, conditions for washing and incubation, enzymatic amplification, photometric measurement, and data analysis. Because total SHBG determination can be measured in a low ionic strength buffer, i.e. PB, the two assays differ only by (a) the nature of the peroxidase-conjugate (anti-SHBG for total SHBG and RCA 120 for dSHBG), (b) the serum dilution, and (c) the standard for calibration. The convenience of this coupled procedure allows extensive studies of various pathological conditions, such as hepatocellular carcinoma, and may thus be useful for a better knowledge of the physiopathology of this disease. The Nova 16 STAT Chemistry Analyzer is designed to provide quick laboratory results of a chemistry profile consisting of glucose, blood urea nitrogen (BUN), creatinine, sodium, potassium, chloride, carbon dioxide, and hematocrit. The analyzer may be of use in the emergency department, the STAT laboratory, or as a mobile laboratory on a movable cart. We obtained the instrument to provide immediate results to the cardiac STAT intensive care unit for the above chemistry constituents. These analytes were previously performed on serum with a Beckman Instrument CX 3 analyzer with an ϳ45 min turnaround time. The major components of the 45 min required to provide these laboratory results were the time to allow specimens to clot, time for centrifugation, and internal laboratory transport times. The Nova 16 wholeblood analyzer eliminates the times required for specimen clotting and centrifugation. Bringing the analyzer physically closer to the patient treatment area or locating it in close proximity of a pneumatic tube system provides further reduction in the turnaround times. We evaluated the performance of the Nova 16 to determine the suitability of this instrument for use in the cardiac STAT intensive care unit and to ascertain the effect of the Nova 16 on turnaround times.
The Nova 16 uses biosensors to determine the concentrations of glucose, BUN, and creatinine (1). The glucose sensor consists of glucose oxidase bonded to a polymeric membrane substrate. ␤-D-glucose is then oxidized to gluconic acid and hydrogen peroxide. The hydrogen peroxide produced is oxidized at the platinum electrode where the hydrogen peroxide is detected. The BUN assay uses an enzyme, urease, that has been chemically bonded to a membrane. The ammonium ion produced is detected with an ammonium ion-selective electrode. The creatinine sensor consists of three enzymes, creatinine amidohydrolase, creatinine amidinohydrolase, and sarcosine oxidase. Creatinine from the sample diffuses through the membrane where the creatinine is converted to hydrogen peroxide. The hydrogen peroxide is oxidized at the platinum electrode. The total carbon dioxide electrode consists of a gas permeable membrane and a pH electrode.
Technical Briefs
Carbon dioxide, both free and protein-bound, is liberated by acidifying the sample. The liberated carbon dioxide diffuses through the membrane and dissolves in the internal filling solution where the resulting change in pH is quantitated by the pH electrode. Sodium, potassium, and chloride are measured using an ion selective electrode (2) .
The correlation studies were performed on whole blood and plasma samples from patients for whom a chemistry profile was requested by the attending physician. The obtained specimens were aliquoted into two samples. One aliquot was centrifuged and then analyzed on a CX3; the remaining aliquot was analyzed on the Nova 16. An EP9 Method (Deming) regression analysis was performed using the EP Evaluator software (David G. Rhoads Associates). The results of the correlation studies were as follows:
Sodium n ϭ 106) (y ϭ 1.02x Ϫ 15 mg/L) Two concentrations of commercially available controls (BioRad) were analyzed with each run during the onemonth evaluation period. These precision results are shown in Table 1 .
The linearities were evaluated using the Nova Linearity Solutions (Sets F-1 to F-4) . The results were analyzed using the EP Evaluator Linearity Module (David G. The manufacturer claims a creatinine linearity from 17.7 to 1768 mol/L. We found considerable scatter below 35.4 mol/L. This is also reflected in the creatinine precision data at lower concentrations. We noticed a considerable flattening of the slope during the three-day life span of the membrane. As a result, the reduction in the absorbanceto-concentration ratio contributed to the high CV observed.
Turnaround times were shorter with the NOVA 16. The laboratory time from receiving the specimen to computer verification (mean Ϯ 2 SD) dropped from an average of 45 Ϯ 14 min to 11 Ϯ 8 min. A similar reduction in the turnaround times was recently reported in another study of the NOVA 16 (3).
The analytical performance of the NOVA 16 was evaluated according to guidelines published by NCCLS (4). The data indicated that the performance of the NOVA 16 (except for creatinine) is equivalent to our CX3. This makes the Nova 16 attractive to use in a rapid response laboratory, an intensive care unit, or emergency room setting. We expect the daily maintenance, membrane replacement, and continuous monitoring of the analyzer to require the attention of an experienced laboratorybased technologist. Because of the continuous use of reagents during priming cycles, reagents are consumed rapidly during those cycles. As a result, the cost per reportable patient result is high if the analyzer is used sparingly. Clinical Chemistry 44, No. 4, 1998 
